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A B S T R A C T
Kidney recipients (n ¼ 51) at risk of cytomegalo-
virus (CMV) disease, and requiring anti-lympho-
cyte globulin therapy because of biopsy-proven
rejection, received high-dose ganciclovir, three
times a week, for a total of nine doses. CMV
disease was observed in seven (14%) patients
within 6 months. Six of these patients were in a
group of 45 CMV-seropositive recipients, and one
was in a high-risk group of CMV-seronegative
recipients. High-dose intravenous ganciclovir,
three times a week, seems to be an efficient, safe
and easy way to prevent CMV disease in patients
treated with anti-lymphocyte globulins for acute
rejection.
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Cytomegalovirus (CMV) continues to be a cause
of substantial morbidity and mortality after solid
organ transplantation. Patients with a donor-
positive:recipient-negative match [1], and patients
undergoing anti-lymphocyte induction or rejec-
tion therapy, are at greatest risk of developing
CMV disease [2,3]. This study evaluated prospec-
tively a targeted prophylaxis with high-dose
infrequent intravenous ganciclovir in patients
treated with anti-lymphocyte globulins for acute
rejection.
From 1994 to 2001, 51 kidney recipients at risk of
CMV disease (donor and ⁄ or recipient serologically
CMV-positive), who required anti-lymphocyte
globulin therapy for biopsy-proven rejection,
received prophylactic intravenous ganciclovir as
a single dose three times a week, for a total of nine
doses, starting on the day of anti-rejection treat-
ment. The dose of ganciclovir was adjusted to the
creatinine clearance (Cl): Cl > 50 mL ⁄min:
10 mg ⁄ kg; Cl 25–49 mL ⁄min: 7.5 mg ⁄ kg; Cl 10–
24 mL ⁄min: 5 mg ⁄kg; Cl < 10 mL ⁄min: 2.5 mg ⁄kg.
CMV antigenaemia was measured with the pp65
assay before and every 1–2 weeks for 6 months
after the acute rejection episode, as described
previously [4,5]. CMV infection was considered
to be present if CMV antigens were detected in
blood leukocytes by the pp65 assay in the absence
of clinical or laboratory signs of a symptomatic
CMV infection. A diagnosis of CMV disease
required positive CMV detection and clinical or
laboratory signs of infection, including fever, leu-
copenia, or organ involvement (hepatitis, pneu-
monitis, colitis, gastritis, chorioretinitis), as agreed
internationally [6–9] Donor and recipient were
both serologically CMV-positive in 31 (61%) cases,
while in six (12%) cases the donor was CMV-
positive and the recipient CMV-negative, and in 14
(27%) cases a CMV-positive recipient received a
CMV-negative graft. In total, 39 (76%) patients
were treated with anti-human rabbit thymocyte
globulins (ATG), six (12%) patients with anti-
human horse thymocyte globulins, and four (8%)
patients with monoclonal anti-CD3 lymphocyte
antibodies (OKT-3). An additional two (4%)
patients were treated initially with ATG, followed
by OKT-3 because of ongoing rejection. No graft
was lost as an immediate consequence of the
rejection episode. Of the 51 patients, 48 received
all nine doses of ganciclovir. One patient, treated
initially with ATG, followed by OKT-3 because of
resistant rejection, received 14 doses of ganciclovir.
Ganciclovir prophylaxis was discontinued because
of significant leucopenia in two patients, one after
five doses, and one after eight doses.
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Seven (14%) of the 51 patients developed CMV
disease within 6 months of anti-rejection treat-
ment despite ganciclovir prophylaxis (Table 1).
Three of these seven patients already had a
positive CMV anti-genaemia before the start of
anti-rejection treatment. The mean time from start
of anti-rejection therapy to CMV disease was
54 days (range: 17–87 days). One patient experi-
enced a CMV primary infection (one of six high-
risk patients). In six patients, CMV reactivation
occurred (six of 45 patients at risk). At the
beginning of anti-rejection treatment, CMV anti-
genaemia was negative in 42 (82%) and already
positive in nine (18%) patients. Of the 42 negative
patients, 23 (55%) became CMV antigenaemia-
positive after the anti-rejection treatment despite
ganciclovir prophylaxis. Four of these developed
CMV disease. CMV antigenaemia was detected at
least once in a total of 32 (63%) of the 51 patients
within 6 months of rejection treatment, while
19 (37%) patients remained negative during the
entire observation period. Six (12%) of the
51 patients were at high risk of CMV primary
infection (i.e., donor CMV-seropositive and
recipient CMV-seronegative). All of these were
CMV antigenaemia-negative when anti-rejection
therapy was started, but CMV antigenaemia was
detected subsequently in four of these patients,
and one patient developed CMV disease. The
cumulative incidence of patients developing CMV
infection or CMV disease is shown in Fig. 1.
The risk of developing CMV infection or CMV
disease after anti-rejection treatment with steroid
pulses and anti-lymphocyte globulins is high [10]
To date, only two studies have investigated the
efficacy of targeted prophylactic daily intraven-
ous ganciclovir therapy in CMV-seropositive kid-
ney recipients treated with anti-lymphocyte
globulins because of acute rejection [11,12]. The
results of the present study show that high-dose
intravenous ganciclovir administered only three
times a week is effective in preventing CMV
disease in patients at risk because of anti-
lymphocyte globulin rejection therapy. An overall
rate of CMV disease of 14% within 6 months was
observed (13% in the group of CMV-seropositive
recipients, and 17% in the high-risk group of
CMV-seronegative recipients). These data indi-
cate a clear benefit in comparison with a previ-
ously reported rate of CMV disease of > 60% in
patients without prophylactic treatment [2,12]
(Table 1). The results in seropositive and sero-
negative patients were also better in comparison
with previous reports that used a daily adminis-
tration of intravenous ganciclovir during the
rejection treatment (Table 1) [12,13].
While the regimen used in the present study
was mostly successful in the prevention of CMV
disease, it did not prevent asymptomatic CMV
infection. Indeed, 55% of patients developed a
positive CMV antigenaemia as a consequence of
the anti-rejection treatment, despite ganciclovir
prophylaxis. This might be a consequence of the
Table 1. Incidence of CMV disease
in the present and previously pub-
lished studies Study
Number of
patients CMV status
Prophylactic regimen
during antibody therapy
because of acute rejection
Incidence of
CMV disease
n (%)
Present study 6 Recipient–
Donor+
Intravenous ganciclovir
three times weekly (nine doses)
1 (17%)
Kletzmayr et al. [13] 18 Recipient–
Donor+
Intravenous ganciclovir
every day (10–14 days)a
10 (55.5%)
Present study 45 Recipient+ Intravenous ganciclovir
three times weekly (nine doses)
6 (13%)
Hibberd et al. [12] 23 Recipient+ Intravenous ganciclovir every daya 5 (22%)
Hibberd et al. [12] 11 Recipient+ No prophylaxis 7 (64%)
aAs long as antibodies were given.
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Fig. 1. Cumulative number of patients developing CMV
infection or CMV disease within 6 months of rejection
therapy (51 patients at risk).
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infrequent dosage interval that permitted a
longer time of virus replication in the absence
of an adequate virus-static ganciclovir blood
concentration. However, the goal of CMV pro-
phylaxis is not to suppress CMV reactivation,
but to avoid the development of CMV disease
until a patient’s specific T-cells are capable of
coping with the virus [5]. As ganciclovir was
administered only three times a week by a
peripheral vein, outpatient treatment was poss-
ible. This allows cost savings and, in contrast to
an oral virus-static therapy, is independent of
the patient’s compliance. The suggested targeted
prophylactic approach is efficient, safe and easy
to perform in an outpatient clinic setting. Future
prophylactic therapies using new oral formula-
tions of antiviral agents [14] should be com-
pared to the regimen described in the present
study.
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A B S T R A C T
From January 2000 to June 2002, 24 Staphylococcus
aureus isolates were recovered from decubitus
ulcers of patients in a geriatric institution, of
which 17 (70.8%) were methicillin-resistant
S. aureus (MRSA). Antibiotic resistance and
DNA macrorestriction (pulsed-field gel electro-
phoresis; PFGE) patterns of the MRSA isolates
were compared with a collection of 161 MRSA
isolates from patients admitted to the institution’s
reference hospital. PFGE revealed the presence of
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